Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation.

Guo S; Deng CX

doi:10.7150/ijbs.25720

Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation.

Guo S ¹,

Deng CX ¹

Affiliations

1. Faculty of Health Sciences, University of Macau, Macau SAR, China.
Authors
Guo S¹
Deng CX¹
(2 authors)

ORCIDs linked to this article

Guo S | 0000-0002-2681-0576

International Journal of Biological Sciences, 13 Nov 2018, 14(14):2083-2093
https://doi.org/10.7150/ijbs.25720 PMID: 30585271 PMCID: PMC6299363

Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Abstract

The cellular environment where tumor cells reside is called the tumor microenvironment (TME), which consists of borders, blood vessels, lymph vessels, extracellular matrix (ECM), stromal cells, immune/inflammatory cells, secreted proteins, RNAs and small organelles. By dynamically interacting with tumor cells, stromal cells participate in all stages of tumor initiation, progression, metastasis, recurrence and drug response, and consequently, affect the fate of patients. During the processes of tumor evolution and metastasis initiation, stromal cells in TME also experience some changes and play roles in both the suppression and promotion of metastasis, while the overall function of stromal cells is beneficial for cancer cell survival and movement. In this review, we examine the effects of stromal cells in TME on metastasis initiation, including angiogenesis, epithelial-mesenchymal transition (EMT) and invasion. We also highlight functions of proteins, RNAs and small organelles secreted by stromal cells in their influences on multiple stages of tumor metastasis.

Free full text

Int J Biol Sci. 2018; 14(14): 2083–2093.

Published online 2018 Nov 13. https://doi.org/10.7150/ijbs.25720

PMCID: PMC6299363

PMID: 30585271

Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation

Sen Guo and Chu-Xia Deng

Author information Article notes Copyright and License information Disclaimer

This article has been cited by other articles in PMC.

Abstract

Keywords: TME, Stromal cells, Metastasis Initiation, Breast Cancer

Introduction

Tumor mass is very heterogeneous and resembles a complicated organ more than a simple accumulation of cells. The environment in which the tumor exists is called the tumor microenvironment (TME) and is composed of blood vessels, lymph vessels, ECM, stromal cells, immune/inflammatory cells, secreted proteins, RNAs and small organelles (Figure (Figure1A)1A) ¹. TME plays indispensable roles in tumor initiation, progression, metastasis, recurrence, and drug resistance.

An external file that holds a picture, illustration, etc.
Object name is ijbsv14p2083g001.jpg

Figure 1

Cells and Molecules (Grey) in TME. (A) TME and cells in TME: CAFs, MSCs, TAMs, Lymphocytes, Endothelial cells, Pericytes, Tumor cells in epithelial status and mesenchymal status. (B) The roles of CAFs in TME: Secret cytokines to affect tumor cells' fates; Remodel ECM; Immunosuppression. (C) The roles of MSCs in TME: Differentiate into other cell types; Secrete cytokines or miRNAs directly, or through exosomes; Transfer organelles through nanotubes; Are recruited by tumor cells. (D) The roles of TAMs in TME: Are recruited by other cells; Secrete cytokines or inflammatory signals to affect tumor cells' fate; Remodel ECM; Immunosuppression. (E) ECM in TME: ECM have many molecules and is remodeled by CAFs, MSCs and TAMs, while it affects the fates of tumors through integrins and other molecules.

Metastasis can be separated into processes of initiation, progression and virulence according to the categories of metastatic genes. Initiation of metastasis mainly includes the processes that occur in preparation for malignant cells to invade and circulate into vessels in TME. Those processes are angiogenesis, epithelial-mesenchymal transformation (EMT) and invasion/intravasation ².

Angiogenesis is essential for tumor and stromal cells to absorb nutrients and exchange air, and it provides a tunnel for cells to move ³. Through EMT, tumor cells ordinarily become more stem-like, aggressive, invasive and have stronger resistance to multiple chemical therapies ⁴. Invasion enables tumor cells to intravasate into the circulatory system and makes it possible to colonize at distant location after circulation ⁵. The process of intravasation is essential for tumor cells to become circulating ⁵. In this article, we review the effects of stromal cells in TME on metastasis initiation.

Functions of the Major Components in Tumor Microenvironment

Stromal Cells in TME

In a tumor, non-transformed cells, which include fibroblasts, mesenchymal stem cells, macrophages, lymphocytes, endothelial cells, and pericytes, participate in tumor progression and regression ¹. The targets that those cells have effects on and the mechanisms they are functioning through are summarized in table table11.

Table 1

The Effects of Stromal Cells on Tumor in TME.

Cell Types		Mechanisms	Targets	Effects on Tumor	References
CAFs		Secretion of Cytokines and Other Factors	Tumor Cells	Drug-Resistance, Proliferation, Metastasis	6, 55, 107
		Secretion of Cytokines and Other Factors	Endothelial Cells	Promote Angiogenesis
		Secretion of ECM proteases and components	ECM	Promote ECM Remodeling
		Suppression of Immune Activities	Cytotoxic T Lymphocytes	Function in Immuno-Suppression
		Recruitment of T Lymphocytes	Progression Promoting T Lymphocytes	Promote Cancer Progression
		Formation of Tumor Barriers	Tumor Cells	Provide Protection
MSCs		Differentiation	Fibroblast and Vascular Pericytes	Form Fibrovascular Network	12-¹⁴
		Differentiation	Other Stromal Cells	Maintain TME
		Secretion of Cytokines	Tumor Cells	Depends on Conditions
		Transfer of Organelles Through Nanotubes	Tumor Cells and Stromal Cells
		Transfer of Proteins Through Exosomes	Tumor Cells and Stromal Cells
		Tumor Tropism	Tumor Cells	Promote Factors Delivery, TME Formation
TAMs		Immune Suppression	Cytotoxic Immune Cells	Promote Cancer Progression	5, 15, 17, 74, 108, 109
		Secretion of Cytokines (Including Inflammatory Factors)	Tumor Cells and Endothelial Cells	Promote Angiogenesis, EMT, Invasion, and Intravasation
		Tropism Leading	Tumor Cells	Promote Intravasation
		Secret ECM proteases and components	ECM	Promote ECM Remodeling
T Lympho-cytes	CD8+	Cytotoxic T Lymphocytes	Tumor Cells	Kill Tumor Cells	110-¹¹⁵
	CD4+ (Th1/Th2)	Secrection of Heterogeneous Cytokines	Lymphocytes (Mainly CD8+ T)	Active Antitumor Immunity
	Th17	Secrection of IL-17 Family Members	Lymphocytes and tumor cells	Regulate Antitumor Immunity and Angiogenesis
	Treg	Suppression of Excessive Immune Activities	Lymphocytes (Mainly CD8+ T)	Mainly Suppress Antitumor Immunity
B Lymphocytes		Secretion of Antibodies	Other Lymphocytes and Tumor Cells	Active T and NK Cells; Kill Tumor Cells	116-¹¹⁹
		Suppression of Immune Activities	T Lymphocytes and NKs	Function in Immuno-Suppression
		Secrection of IL-10	T Lymphocytes and Tumor Cells	Convert T into Treg; Regulate Proliferation and Metastasis of Tumor Cells
Endothelial Cells		Line Vasculatures	Blood Vessels	Promote Angiogenesis	18, 120-122
		Diameter Extending	Blood Vessels	Promote Extravasation
		Abnormal Growth	Blood Vessels	Produce Hypoxia in TME, Regulate Proliferation and Therapy Resistance of Tumor Cells
		ECM Remodeling	ECM	promote ECM Remodeling
		Immune Responses Altering (Lymphatic Vessels)	Immune System	Promote Lymphangiogenesis and cancer progression
Pericytes		Low Coverage around Vasculatures	Vasculatures	Promote Metastasis	19, 123

Fibroblasts are the predominant cell type in TME and are associated with all stages of the cancer. These activated fibroblasts in tumors are called myo-fibroblasts or Cancer-Associated-Fibroblasts (CAFs). CAFs enhance tumorigenesis, angiogenesis and metastasis by secreting growth factors and cytokines and promoting TME remodeling through the secretion of Matrix Metalloproteinases (MMPs), ECM components and other enzymes (Table (Table1)1) ⁶. For immune activity, CAFs suppress the activity of cytotoxic T lymphocytes and recruit lymphocytes that produce inflammatory signals to promote cancer progression (Table (Table1).1). It has been reported that CAFs can reconstitute anti-metastatic TME into a pro-metastatic TME ⁷. This might be due to the function of stroma derived factors. Fibrinogen-like protein 2 in TME activates CAFs and causes them to become pro-tumorigenic, which promotes the accumulation of myeloid-derived suppressor cells (MDSCs) through the secretion of CXCL12. This then affects tumorigenesis and cancer progression ⁸. Additionally, CAFs facilitate resistance of anti-cancer drugs or therapies and provide protection or pro-proliferation factors in cancer cells (Figure (Figure1B)1B) ⁶. Currently, more genes in fibroblasts inside TME have been shown to be potential marks for the cancer progression, like caveolin-1 ⁹, which can be developed as therapy targets.

Mesenchymal Stem Cells (MSCs) are a kind of multipotent cell that can differentiate into multiple mesenchymal cell lineages, including multipotent stromal cells or mesenchymal stromal cells ¹⁰. MSCs have been reported to cure injured cells or tissues by differentiating into cells of the same type with injured cells. They interact with tumor cells via the secretion of growth factors or cytokines and by transferring mitochondria or microRNAs through tunneling nanotubes or exosomes (Table (Table1)1) ¹⁰. MSCs are tumor tropisms and attract the attention of different groups to explore specific delivery vehicles for tumor therapy ¹¹^,¹². Residing in tumors, MSCs form a fibrovascular network by differentiating into CAFs and vascular pericytes ¹³. While the function of MSCs in cancer progression is diverse under different conditions, any changes can switch the functions of MSCs from tumor promotion into suppression (Figure (Figure1C)1C) ¹⁴.

Macrophages play important roles in inflammation, immunology, development and wound healing ¹⁵. They can also be recruited to TME by tumor cells or MSCs through the secretion of specific factors, then they become polarized and are referred to as Tumor-Associated Macrophages (TAMs) ¹⁶. TAMs suppress immune activity and promote cancer progression, which is similar to their functions in wound healing (Table (Table1)1) ¹⁷. The balance of the inflammation significantly influences the effects TAMs have on tumors ¹⁵. Also, macrophages remodel ECM by organizing ECM and secreting ECM components and enzymes (Figure (Figure1D)1D) ¹⁷.

In this article, we focus on three types of stromal cells including CAFs, MSCs and TAMs. Additional types of non-transformed cells in TME are summarized in Table Table1.1. Lymphocytes have paradoxical functions in TME, although T cells and B cells can be found in invasive tumor margins in draining lymphoid organs or lymphoid structures adjacent to TME ¹. Endothelial cells in TME compose vasculatures and lymphatic vessels that branch to the ends of the tumor, which is needed for tumor growth and metastasis ¹⁸. Similarly, pericytes or perivascular stromal cells function in structures in the support of blood vessels (Table (Table1)1) ¹⁹.

ECM in TME

ECM functions as a scaffold for the cells in TME and plays a dynamic role in cancer progression, especially as an essential regulator of invasive processes ¹. ECM is a complicated system of proteins, glycoproteins, proteoglycans and polysaccharides, which contains multiple growth factors and builds a tight interaction with cells in TME ²⁰. In healthy tissue, ECM plays a tumor suppressing role, while it becomes abnormal in tumors and plays a tumor promoting role ²¹. The components functioning in tumor promoting roles in ECM are induced in TME ²¹^,²² and they influence tumor cells through interacting with integrins (Figure (Figure1E)1E) ²³.

Recently, NK cells are reported to control metastasis formation through influencing tumor architecture by regulating the secretion of FN1, an important ECM component ²⁴. This highlights the function of interactions between stromal cells and ECM in TME.

Secreted Factors in TME

As summarized in table table2,2, secreted factors in TME function as signals between cells, or tools in ECM remodeling, including cytokines, integrins, proteases and microRNAs ²⁵.

Table 2

The Effects of Secreted Factors on Tumor Cells in TME.

Factors	Classifications (Examples)		Mechanisms	Targets	Effects on Tumor	References
Cytokines	Inflammatory Factor	Tumor Necrosis Factor (TNF-α)	Induce NF-κB, TGF-β and Apoptosis	Tumor and Stromal Cells	Regulate Growth, Angiogenesis, and Invasion	124
	Inflammatory Factor	Interleukin (IL-6)	Induce JAK/STAT Pathway	Tumor and Endothelial Cells	Promote EMT, Proliferation and Inhibit Apoptosis	125
	Growth Factor	TGF-β	Immune and Inflammatory Suppression, EMT Induction and Regulation of other Growth Factors	Tumor Cells and Stromal Cells	Early Stage: Tumor Suppressor; Late Stage: Promote Invasion and Metastasis	56, 78, 126
		VEGF	Promote the Migration and Proliferation of Endothelial Cells	Endothelial Cells	Promote EMT, Angiogenesis, and Intravasation	127-¹²⁹
		EGF	Promote Growth, Recruit Tumor Cells, Induce EMT TFs	Tumor Cells and Stromal Cells	Promote Proliferation, EMT and Intravasation	128, 129
		FGF	Promote Proliferation, Angiogenesis	Endothelial Cells	Promote EMT, and Angiogenesis	127, 128, 130
		PDGF	Induce EMT TFs, Stimulate VEGF and FGF while Stimulate Tsp-1	Tumor Cells, Fibroblasts, Endothelial Cells and Pericytes	Affect Intravasation and Immune Surveillance; Promote Angiogenesis, Fibroblast recruitment, Tumor growth and Metastasis	131, 132
		HGF	Induce EMT TFs	Tumor Cells	Promote EMT	55
	Chemokines (CXCL12 and CXCR4)		Chemotaxis; Recruit Stromal Cells or Tumor Cells in TME	Tumor Cells and Stromal Cells	Influence Growth, Proliferation and Migration of Tumor Cells and Stromal Cells	133, 134
Integrins	Noncovalently Linked α and β Subunits (like α₄β₁ and α_vβ₃, α₅β₁)		Regulate Cytoskeleton; Cell-Cell/Cell-Matrix Signal Transferring; Maintaining of Cell-Matrix Adhesions; Tissue Remodeling	Cell-Cell and Cell-Matrix Contact in TME	Mostly Promote Angiogenesis, Intravasation and Metastasis	28, 83, 135
Proteases	Matrix Metalloproteinases (MMPs)		Degrade ECM, Basement Membrane and Cell-Cell/Cell-Matrix Junctions; Release Factors from ECM	ECM, and Junctions	Promote Invasion, Metastasis, Growth and Angiogenesis while Regulate Apoptosis	33, 34, 59
Proteases	urokinase-type Plasminogen Activator (uPA)		Activate Plasminogen into Plasmin	Endothelial Cells	Promote Intravasation	5, 83

Cytokines are kind of small proteins that have low molecular weights, which mediate the communication between cells ²⁶. Cytokines in TME, including tumor necrosis factor, interleukins, growth factors and chemokines, regulate the progression of cancer and determine the fate of stromal cells. This is depended on the balance of their pro- and anti-functions in inflammation, proliferation, tumorigenesis, migration and apoptosis (Table (Table2)2) ²⁷.

Integrins are integral membrane proteins and a large family of cell surface receptors ²⁸. Integrins are essential in the signaling and transfer of information between cells or between a cell and the ECM. They are also essential in maintaining cell-matrix adhesions. Irregular cell-cell adhesions, caused by disrupted integrins, are signs of cancer (Table (Table2).2). In TME, the expressions of metastasis-promoting integrins are enhanced, while those suppressing proliferation, survival and migration are repressed ²⁸. Recently, some groups are focusing on exosome derived integrins as the researches on exosome are increasing ²⁹. Also, integrins are reported to affect internal activities of tumor, like nuclear alteration ³⁰.

Extracellular proteolysis plays an essential role in tissue homeostasis and TME ³¹^,³². Among these proteinases that mediate the proteolysis of ECM, matrix metalloproteinases (MMPs) have the closest relationship with cancer progression (Table (Table2)2) ³³. It is already known that ECM degradation that is mediated by MMPs promotes the invasion and metastasis of cancer ³³. Furthermore, recent research indicates that MMPs promote tumor growth, angiogenesis and regulate apoptosis and some MMPs function in tumor suppression (Table (Table2).2). Thus, MMPs are also a family of proteins with paradoxical role in TME ³⁴.

MicroRNAs are endogenous, small non-coding RNAs, each of which has 18-24 nucleotides. They negatively regulate target mRNAs, post-transcriptionally by disrupting transcription or translation ³⁵. MicroRNAs participate in several pathways and function in the regulation of different components of TME ³⁶. Besides microRNA, lncRNA or long non-coding RNA is also a potent participant that is secreted in TME. Some lncRNAs function in the communication between TME and stromal cells, like transforming fibroblasts to be tumor-promoting ³⁷.

The Effects of Stromal Cells on Metastasis Initiation

The Effects of Stromal Cells on Angiogenesis

Angiogenesis plays an initial role in the process of metastasis, which provides a way for aggressive tumor cells to leave primary tumors and move to distant metastatic sites. In the process of angiogenesis, stromal cells in TME play promoting roles. We introduce these regulatory pathways involving stromal cells in the following section ³⁸.

Stromal cells affect the fate of TME through the secretions of these angiogenesis-promoting factors and angiogenesis-inhibiting factors. Among these factors, VEGF is the most potent. VEGF promotes the migration and proliferation of endothelial cells and the permeability of vessels ³⁹^,⁴⁰. In cells, activated Ras and PI3K signal pathways trigger increased transcription of VEGF and other factors that regulate VEGF, like TGF-β, PDGF and bFGF ⁴¹.

Thrombospondin-1 (Tsp-1) is a potent endogenous antiangiogenic protein. It functions by binding to CD36 on the surface of endothelial cells and makes them insensitive to VEGF and bFGF. Tsp-1 also inactivates MMP9 through binding; this decreases the release of VEGF and bFGF from ECM. Thus, in aggressive tumors, repression of Tsp-1 is required and common ⁴²^-⁴⁴. The PI3K-Rho-ROCK-Myc pathway is active in several types of human breast cancer cells and it represses Tsp-1 via phosphorylation. This pathway is called the “angiogenic switch” due to its cell-autonomous character ⁴⁵. Some tumor cells could overcome the inhibitory function of Tsp-1 by producing increased levels of VEGF ³⁸.

CAFs are the predominant stromal cells in TME and function as a scaffold along with ECM ⁶. ECM secreted by CAFs results in a hypoxic environment inside the tumor. This effect results in the recruitment of TAMs and triggers TAMs and tumor cells to produce more HIF-1α and VEGF ³⁸. HIF-1α induces tumor and stromal cells to produce more VEGF and other pro-angiogenesis factors. VEGF contributes to the recruitment and activation of endothelial cells ⁴⁶. Cytokines secreted by CAFs also contribute to angiogenesis. CXCL12 (Stromal Cell-Derived Factor 1, SDF1), a chemokine secreted by CAFs, promotes angiogenesis through the recruitment of endothelial progenitor cells (EPCs) into TME ⁴⁷ and its receptor, CXCR4, has already become a novel target for drug delivery ⁴⁸^,⁴⁹. CAFs also can secrete VEGF directly, as well as other growth factors that promote angiogenesis by inhibiting the angiogenesis-suppressing role of TSP1 ⁶.

Injection of tumor cells with MSCs into mice produces twice the vessels than injecting tumor cells alone. MSCs promote angiogenesis directly through the secretion of VEGF and indirectly, through the secretion of other growth factors, like TGF-β, to influence the effect of VEGF and the functions of other cells ⁵⁰. In a recent clinical therapy, researchers found that radiation therapy stimulates the secretion of inflammatory mediators, like SDF-1α and PDGF-B, from tumor cells. These signals increase the recruitment of MSCs through the binding of CXCR4 or PDGFR-β and enhancement of vasculogenesis by triggering MSCs to differentiate into pericytes ⁵¹.

Hypoxia produced by tumors may recruit TAMs to those hypoxic sites, and then induce TAMs to produce HIF1-α and enhance its function on transcription factors. This increases the production of pro-angiogenesis factors like VEGF, basic Fibroblast Growth Factor (bFGF), TNFα, and CXCL12 ³^,³⁸. Conversely, Colony-Stimulating Factor (CSF) increases the production of metalloelastase via macrophages ⁵². Metalloelastase cleaves plasminogen into several small proteins, including the antiangiogenic protein, angiostatin ⁵³.

The Effects of Stromal Cells on EMT

EMT is the transition of tumor cells from epithelial status to mesenchymal status and, therefore, gives migrating and invasive abilities to these tumor cells ⁵⁴. Stromal cells in TME also play crucial roles in EMT, together with multiple factors that are illustrated in Figure Figure22 and are discussed below.

An external file that holds a picture, illustration, etc.
Object name is ijbsv14p2083g002.jpg

Figure 2

The Effects of TME on Epithelial-Mesenchymal Transition. In TME, stromal cells, like CAFs, MSCs and TAMs, secrete growth factors like TGF-β, PDGF, EGF and HGF, along with miRNAs like miR21 and miR200 family, to regulate EMT through EMT transcription factors or RAS/RAF/MEK/ERK/MAPK pathway. They also secret MMPs to degrade ECM and junctions between cells and cells with ECM to “free” tumor cells. Inflammatory signals secreted by TAMs, like TNF-α and IL-6, trigger EMT through TGF-β or NF-κB pathways. Meanwhile, hypoxia produced in TME up-regulate HIFα-1 and trigger EMT through the NF-κB pathway.

In TME, CAFs, MSCs, and TAMs affect EMT primarily through the secretion of growth factors like TGF-β, PDGF, EGF, VEGF, HGF or MMPs like MMP1, MMP2, and MMP9 ⁴^,⁵⁵.

There are several classes of growth factors functioning in the process of EMT. The key regulators among them are TGF-β family members, which may be secreted by stromal cells and tumor cells ⁵⁶^,⁵⁷. TGF-β induces EMT mainly through two pathways: Smads dependent and Smads independent pathways. In the Smads dependent pathway, TGF-β induces phosphorylation and heterodimer formation of Smad2 and Smad3 by binding to membrane-bound TGF-β receptors ⁵⁸. The Smad2/Smad3 complex then interacts with Smad4 and is transferred into the nucleus where they induce EMT Transcription Factors (EMT TFs) such as snail, twist, and ZEB ⁵⁸. In the Smads independent pathway, TGF-β induces EMT by activating RAS/ERK, JNK, p38 MAPK pathways that are cooperated with integrins or simply through integrin interactions ⁴.

Growth factors besides TGF-β (like EGF, FGF, HGF, VEGF and PDGF), also induce EMT via the induction of EMT TFs and activation of the RAS/RAF/MEK/ERK/MAPK pathway ⁵⁵.

Matrix metalloproteinases (MMPs) also play important roles in the process of EMT. MMPs can degrade cell-matrix adhesions as well as cell-cell junctions that assist the morphological transition from epithelial to mesenchymal. MMPs also release EMT regulators by degrading ECM into TME ⁵⁹.

Besides secreting growth factors and MMPs, TAMs also participate in this process through the secretion of inflammatory factors like TNF-α and IL-6 ⁶⁰^-⁶². Those inflammatory factors trigger EMT by inducing TGF-β or NF-κB pathways. Additionally, TNF-α also induce EMT through the triggering of ROS. IL-6 does it by activating the JAK/STAT3 pathway ⁶³^,⁶⁴. While, enhanced expression levels of COX2 in TAM is positively correlated to the secretion of COX2, IL-6, PGE₂ and MMP9, and promotes the process of EMT of breast cancer cells by activating the Akt pathway ⁶⁵.

Recently, Cédric Blanpain reported that tumor cells in the EMT process show progressive states from epitheial to mesenchymal ⁶⁶. Further, they determined the microenvironmental changes company with the progressing EMT states. They also found that the number and density of endothelial cells and lymphatic cells (especially macrophages) were increased in the progressing of EMT process. This suggests interactions between blood vessel formation and inflammatory with EMT ⁶⁶. Stromal cells also can release MicroRNAs like miR21 and miR200 family members through exosomes to communicate with cancer cells and induce EMT ⁶⁷^-⁶⁹.

The Effects of Stromal Cells on Invasion and Intravasation

Invasion is a process in which tumor cells migrate from one place to another by breaking the ECM or basement membrane ⁷⁰. For example, the migration of tumor cells from primary tumors into sites near vessels is a typical invasion ⁷¹.

In the process of invasion, MMPs are secreted by stromal cells or tumor cells and degrade the ECM and basement membrane in the path of tumor cell migration. MMPs also regulate the skeleton of tumor cells that is related to cell motility and invasion ⁷².

Conversely, intravasation is the process by which tumor cells migrate into blood or lymph vessels through Trans-Endothelial Migration (TEM). There are two kinds of intravasation: paracellular and transcellular. Most tumor cells undergo paracellular intravasation. In the process of paracellular TEM (Figure (Figure3),3), tumor cells migrate across the vessel walls composed of endothelial cells by opening the junctions between endothelial cells. In this process, endothelial cells undergoing retraction to make space for tumor cells ⁵. In transcellular intravasation, tumor cells migrate into the vessels directly across the body of endothelial cells. Endothelial cells undergo degradation of skeletons and contraction in this process ⁷³.

An external file that holds a picture, illustration, etc.
Object name is ijbsv14p2083g003.jpg

Figure 3

The Effects of TME on Intravasation. Tumor cells in mesenchymal status is leaded by Vessel Associated/Tumor Associated Macrophages and invade toward the vessel wall, tumor cells in turn, recruit macrophages. Growth factors, chemokines, proteases and inflammatory factors that are secreted by stromal or tumor cells, promote the opening of junctions between endothelial cells. Factors promoting angiogenesis enhance intravasation due to the loose junction between endothelial cells and low coverage of pericytes in newly formed blood vessels.

There are also multiple stromal cells and factors that function in the process of intravasation in TME ⁵^,⁷⁴. Besides endothelial cells, Vessel Associated Macrophages (VAMs) or Tumor Associated Macrophages (TAMs) are crucial to this process. VAMs attract tumor cells to invade toward vessels through the secretion of EGF, meanwhile, tumor cells secret SCF to recruit macrophages. These processes build EGF/SCF paracrine interaction which depends on the contact with each other ⁷⁵. TNF-α, which is secreted by macrophages, may trigger the retraction of endothelial cells by binding to its receptors while it also can make vessels more permeable for tumor cells by inducing an apoptosis signal, along with other apoptotic ligands ⁷⁶.

Other stromal cells like MSCs and CAFs regulate the process of intravasation through the secretion of TGF-β, PDGF, CXCL12/CXCR4 and MMPs ⁵.

TGF-β promotes EMT and invasion ⁵⁷ while plays a paradoxical role in intravasation. Long-term exposure of TGF-β promotes the proliferation of endothelial cells and inhibits the crossing of tumor cells into vessels. Transient signals induced by TGF-β promote intravasation through the down-regulation of CSF1, LHX2/PDGFβ and Twist ⁵^,⁷⁷^,⁷⁸. Similarly to VEGF, TGF-β also promotes the opening of junctions between endothelial cells by inhibiting the complex of VE-Cadherin and β-catenin ⁷⁴. Besides TGF-β itself, Latent TGF-β Binding Protein 3 (LTBP3) promotes the formation of intravasation involved angiogenesis ⁷⁹ and suggests that more investigation on this factor is needed.

Urokinase-type Plasminogen Activator (uPA) is the soluble portion of the protease system named uPA/PAR. This soluble portion can be secreted by CAFs, MSCs and macrophages ⁸⁰^-⁸². Its function depends on its binding to the PAR receptor and this binding is promoted by MMP1. After uPA/PAR binding, these proteins may cleave plasminogen into plasmin, which cleaves CDCP1. Cleaved CDCP1 promotes the intravasation via the FAK/PI3K pathway that cooperates with β₁-integrin ⁵^,⁸³.

Angiogenesis is highly related to the process of intravasation. Those angiogenic stimulators, like VEGF, bFGF and PDGF, promote intravasation by promoting angiogenesis to provide larger and more permeable vessels. These factors also promote the invasion of tumor cells toward vessels ⁷⁴^,⁷⁷. There are also several microRNAs that facilitate intravasation of breast cancer cells, like miR10b and miR200c ⁸⁴^,⁸⁵.

Conclusion and Future Aspects

Stromal cells are indispensable in tumors and TME. They are recruited by tumor cells and affect metastasis initiation through the regulation of tumor cells and themselves.

In TME, CAFs mainly play promoting roles in metastasis initiation (Table (Table1).1). This might be due to its functions in immune suppression, ECM remodeling and the secretion of pro-inflammatory and pro-metastatic cytokines, enzymes and microRNAs ⁶⁷. MSCs in TME affect metastasis initiation by differentiating into other stromal cells or secreting multiple factors. Currently, many labs are focused on “cell therapy”, based on the research on MSCs. TAMs are also potent stromal cells in TME. In metastasis initiation, they function with at least three major features. First, they secret inflammatory signals like TNF-α and IL-6, then activate angiogenic or EMT-promoting pathways. A recent report showed that COX2 in TAMs is essential to their function with this feature ⁶⁵. Second, they regulate the process of intravasation by forming EGF/SCF paracrine interaction with tumor cells. Third, TAMs also secret multiple kinds of cytokines like IGF ⁸⁶. Other than those three types, TAMs also transfer iron to tumor and promote tumor cell proliferation ⁸⁷, which open a new door for research on TAMs.

Other than these types of stromal cells, there are still several types of non-transformed cells in TME like osteoblasts and osteoclasts in bone metastasis ⁸⁸, platelets and monocytes in angiogenesis and tumor progression ⁸⁹^,⁹⁰, and neutrophils in metastatic tumors ⁹¹. The participation of stromal cells in TME not only gives researchers more targets and avenues, but also results in more uncontrolled factors in cancer research.

Recently, a group put forward a method that defined the sites of metastatic tumor microenvironment by staining three parts: migrative cancer cells, TAMs and endothelial cells ⁹². They named these sites TMEM (Tumor Microenvironment of Metastasis) and found the number and status of these sites correlate with the metastasis of the tumor. Furthermore, they explored that TMEM mediated neoadjuvant chemotherapy induced the metastasis of breast cancer ⁹³, which is crucial in the clinical application and still a hot-point in current drug development ⁹⁴.

Exosomes in TME have been showed to participate in multiple stages of cancer progression, including metastasis initiation ⁹⁵. They are good mediators of information transfer between cells and their cargos include miRNAs, mRNAs, DNAs and proteins ⁹⁶. Exosomes could also be released by stromal cells and participate in the regulation of cancer progression, especially those from MSCs ⁹⁷^-⁹⁹.

Stromal cells also undergo metabolic changes in TME, which contributes to the fates of tumor cells. Reports have shown that TAMs and CAFs undergo metabolic reprograming of glucose, lipids and amino acids in TME ¹⁰⁰^,¹⁰¹. While, tumor cells probably enhance the aerobic glycolysis of TAMs and CAFs and contribute to their activation ¹⁰²^,¹⁰³, and these stromal cells should reshape the metabolism of TME and convert nutrients into forms that are absorbable for tumor cells ¹⁰². Metabolism also changes the pH value in TME. One group showed that acidification of extracellular fluids promotes the activation of CAF from MSC ¹⁰⁴. It would be a future aspect to explore whether and how metabolism functions in the metastasis of tumor cells in TME.

Currently, stromal cells could also be used in combining therapies with immune therapy. Firstly, immune therapy modifies TME to enrich preferred phenotypes and increase immune effector cells, while decreasing immune suppressive cells. Secondly, immune therapy activates, triggers and regulates stromal cells, while stromal cells release chemokines or other factors to recruit or regulate immune cells ¹⁰⁵^,¹⁰⁶. These processes are all potential targets in the future combination of therapies.

Acknowledgments

We thank the members of the Deng laboratory for critical discussions. This work is supported by the Chair Professor Grant (CPG2017-00026-FHS), MYRG2016-00132-FHS and MYRG2016-00139 of University of Macau and FDCT grants (065/2015/A2 and 094/2015/A3) to Chu-Xia Deng. The authors declare no conflict of interest.

References

1. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–6. [Abstract] [Google Scholar]

2. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8:341–52. [Abstract] [Google Scholar]

3. Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol. 2014;41:235–51. [Abstract] [Google Scholar]

4. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–8. [Europe PMC free article] [Abstract] [Google Scholar]

5. Chiang SP, Cabrera RM, Segall JE. Tumor cell intravasation. Am J Physiol Cell Physiol. 2016;311:C1–C14. [Europe PMC free article] [Abstract] [Google Scholar]

6. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98. [Abstract] [Google Scholar]

7. Murata T, Mekada E, Hoffman RM. Reconstitution of a metastatic-resistant tumor microenvironment with cancer-associated fibroblasts enables metastasis. Cell Cycle. 2017;16:533–5. [Europe PMC free article] [Abstract] [Google Scholar]

8. Zhu Y, Zhang L, Zha H, Yang F, Hu C, Chen L. et al. Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer. Int J Biol Sci. 2017;13:804–14. [Europe PMC free article] [Abstract] [Google Scholar]

9. Shen XJ, Zhang H, Tang GS, Wang XD, Zheng R, Wang Y. et al. Caveolin-1 is a modulator of fibroblast activation and a potential biomarker for gastric cancer. Int J Biol Sci. 2015;11:370–9. [Europe PMC free article] [Abstract] [Google Scholar]

10. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther. 2016;7:125. [Europe PMC free article] [Abstract] [Google Scholar]

11. Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M. et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 2010;66:144–56. discussion 56-7. [Europe PMC free article] [Abstract] [Google Scholar]

12. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A. et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27:2614–23. [Europe PMC free article] [Abstract] [Google Scholar]

13. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009;4:e4992. [Europe PMC free article] [Abstract] [Google Scholar]

14. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011;29:11–9. [Europe PMC free article] [Abstract] [Google Scholar]

15. Brady NJ, Chuntova P, Schwertfeger KL. Macrophages: Regulators of the Inflammatory Microenvironment during Mammary Gland Development and Breast Cancer. Mediators Inflamm. 2016;2016:4549676. [Europe PMC free article] [Abstract] [Google Scholar]

16. Shaked Y, McAllister S, Fainaru O, Almog N. Tumor dormancy and the angiogenic switch: possible implications of bone marrow- derived cells. Curr Pharm Des. 2014;20:4920–33. [Abstract] [Google Scholar]

17. Liguori M, Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel) 2011;3:3740–61. [Europe PMC free article] [Abstract] [Google Scholar]

18. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307. [Europe PMC free article] [Abstract] [Google Scholar]

19. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21:193–215. [Abstract] [Google Scholar]

20. Mongiat M, Andreuzzi E, Tarticchio G, Paulitti A. Extracellular Matrix, a Hard Player in Angiogenesis. Int J Mol Sci; 2016. p. 17. [Europe PMC free article] [Abstract] [Google Scholar]

21. Robertson C. The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking. Exp Cell Res. 2016;343:73–81. [Abstract] [Google Scholar]

22. Insua-Rodriguez J, Oskarsson T. The extracellular matrix in breast cancer. Adv Drug Deliv Rev. 2016;97:41–55. [Abstract] [Google Scholar]

23. Singh C, Shyanti RK, Singh V, Kale RK, Mishra JPN, Singh RP. Integrin expression and glycosylation patterns regulate cell-matrix adhesion and alter with breast cancer progression. Biochem Biophys Res Commun. 2018;499:374–80. [Abstract] [Google Scholar]

24. Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S. et al. NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018;48:107–19. e4. [Abstract] [Google Scholar]

25. Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63:571–82. [Europe PMC free article] [Abstract] [Google Scholar]

26. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185. [Europe PMC free article] [Abstract] [Google Scholar]

27. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7:651–8. [Europe PMC free article] [Abstract] [Google Scholar]

28. Alphonso A, Alahari SK. Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia. 2009;11:1264–71. [Europe PMC free article] [Abstract] [Google Scholar]

29. Paolillo M, Schinelli S. Integrins and Exosomes, a Dangerous Liaison in Cancer Progression. Cancers (Basel); 2017. p. 9. [Europe PMC free article] [Abstract] [Google Scholar]

30. Madrazo E, Conde AC, Redondo-Munoz J. Inside the Cell: Integrins as New Governors of Nuclear Alterations? Cancers (Basel); 2017. p. 9. [Europe PMC free article] [Abstract] [Google Scholar]

31. Craddock RJ, Hodson NW, Ozols M, Shearer T, Hoyland JA, Sherratt MJ. Extracellular matrix fragmentation in young, healthy cartilaginous tissues. Eur Cell Mater. 2018;35:34–53. [Abstract] [Google Scholar]

32. Kumar S, Kulkarni R, Sen S. Cell motility and ECM proteolysis regulate tumor growth and tumor relapse by altering the fraction of cancer stem cells and their spatial scattering. Phys Biol. 2016;13:036001. [Abstract] [Google Scholar]

33. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67. [Europe PMC free article] [Abstract] [Google Scholar]

34. Noel A, Gutierrez-Fernandez A, Sounni NE, Behrendt N, Maquoi E, Lund IK. et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol. 2012;3:140. [Europe PMC free article] [Abstract] [Google Scholar]

35. Manasa VG, Kannan S. Impact of microRNA dynamics on cancer hallmarks: An oral cancer scenario. Tumour Biol. 2017;39:1010428317695920. [Abstract] [Google Scholar]

36. Kuninty PR, Schnittert J, Storm G, Prakash J. MicroRNA Targeting to Modulate Tumor Microenvironment. Front Oncol. 2016;6:3. [Europe PMC free article] [Abstract] [Google Scholar]

37. Ding L, Ren J, Zhang D, Li Y, Huang X, Hu Q, A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33. Carcinogenesis; 2018. [Abstract] [Google Scholar]

38. Watnick RS. The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med. 2012;2:a006676. [Europe PMC free article] [Abstract] [Google Scholar]

39. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC. et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. FASEB J. 2015;29:227–38. [Abstract] [Google Scholar]

40. Liu S, Jiang M, Zhao Q, Li S, Peng Y, Zhang P. et al. Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2. Oncol Rep. 2014;32:2477–84. [Abstract] [Google Scholar]

41. Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci; 2018. p. 19. [Europe PMC free article] [Abstract] [Google Scholar]

42. Jeanne A, Schneider C, Martiny L, Dedieu S. Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front Pharmacol. 2015;6:252. [Europe PMC free article] [Abstract] [Google Scholar]

43. Radziwon-Balicka A, Santos-Martinez MJ, Corbalan JJ, O'Sullivan S, Treumann A, Gilmer JF. et al. Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis. 2014;35:324–32. [Abstract] [Google Scholar]

44. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF. et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 2009;23:3368–76. [Europe PMC free article] [Abstract] [Google Scholar]

45. Kazerounian S, Lawler J. Integration of pro- and anti-angiogenic signals by endothelial cells. J Cell Commun Signal. 2018;12:171–9. [Europe PMC free article] [Abstract] [Google Scholar]

46. Hoeppner LH, Sinha S, Wang Y, Bhattacharya R, Dutta S, Gong X. et al. RhoC maintains vascular homeostasis by regulating VEGF-induced signaling in endothelial cells. J Cell Sci. 2015;128:3556–68. [Europe PMC free article] [Abstract] [Google Scholar]

47. Zhang M, Qiu L, Zhang Y, Xu D, Zheng JC, Jiang L. CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells. Sci Rep. 2017;7:8289. [Europe PMC free article] [Abstract] [Google Scholar]

48. Miller EJ, Jecs E, Truax VM, Katzman BM, Tahirovic YA, Wilson RJ, Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in vitro ADMET Properties. J Med Chem; 2018. [Abstract] [Google Scholar]

49. Ziegler ME, Hatch MM, Wu N, Muawad SA, Hughes CC. mTORC2 mediates CXCL12-induced angiogenesis. Angiogenesis. 2016;19:359–71. [Europe PMC free article] [Abstract] [Google Scholar]

50. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL. et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A. 2009;106:3806–11. [Europe PMC free article] [Abstract] [Google Scholar]

51. Wang HH, Cui YL, Zaorsky NG, Lan J, Deng L, Zeng XL. et al. Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. Cancer Lett. 2016;375:349–59. [Abstract] [Google Scholar]

52. Tsuji T, Kelly NJ, Takahashi S, Leme AS, Houghton AM, Shapiro SD. Macrophage elastase suppresses white adipose tissue expansion with cigarette smoking. Am J Respir Cell Mol Biol. 2014;51:822–9. [Europe PMC free article] [Abstract] [Google Scholar]

53. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R. et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004;64:5378–84. [Abstract] [Google Scholar]

54. Liu Y, Liu B, Zhang GQ, Zou JF, Zou ML, Cheng ZS. Calpain inhibition attenuates bleomycin-induced pulmonary fibrosis via switching the development of epithelial-mesenchymal transition. Naunyn Schmiedebergs Arch Pharmacol; 2018. [Europe PMC free article] [Abstract] [Google Scholar]

55. Jing Y, Han Z, Zhang S, Liu Y, Wei L. Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci. 2011;1:29. [Europe PMC free article] [Abstract] [Google Scholar]

56. Morrison CD, Parvani JG, Schiemann WP. The relevance of the TGF-beta Paradox to EMT-MET programs. Cancer Lett. 2013;341:30–40. [Europe PMC free article] [Abstract] [Google Scholar]

57. Ma M, He M, Jiang Q, Yan Y, Guan S, Zhang J. et al. MiR-487a Promotes TGF-beta1-induced EMT, the Migration and Invasion of Breast Cancer Cells by Directly Targeting MAGI2. Int J Biol Sci. 2016;12:397–408. [Europe PMC free article] [Abstract] [Google Scholar]

58. Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111–23. [Europe PMC free article] [Abstract] [Google Scholar]

59. Nistico P, Bissell MJ, Radisky DC. Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol; 2012. p. 4. [Europe PMC free article] [Abstract] [Google Scholar]

60. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71. [Abstract] [Google Scholar]

61. Wang S, Yan Y, Cheng Z, Hu Y, Liu T. Sotetsuflavone suppresses invasion and metastasis in non-small-cell lung cancer A549 cells by reversing EMT via the TNF-alpha/NF-kappaB and PI3K/AKT signaling pathway. Cell Death Discov. 2018;4:26. [Europe PMC free article] [Abstract] [Google Scholar]

62. Wu ST, Sun GH, Hsu CY, Huang CS, Wu YH, Wang HH. et al. Tumor necrosis factor-alpha induces epithelial-mesenchymal transition of renal cell carcinoma cells via a nuclear factor kappa B-independent mechanism. Exp Biol Med (Maywood) 2011;236:1022–9. [Abstract] [Google Scholar]

63. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F. et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007;26:7445–56. [Abstract] [Google Scholar]

64. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008;104:733–44. [Abstract] [Google Scholar]

65. Gan L, Qiu Z, Huang J, Li Y, Huang H, Xiang T. et al. Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci. 2016;12:1533–43. [Europe PMC free article] [Abstract] [Google Scholar]

66. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Identification of the tumour transition states occurring during EMT. Nature; 2018. [Abstract] [Google Scholar]

67. Wang Z, Tan Y, Yu W, Zheng S, Zhang S, Sun L. et al. Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells. Int J Biol Sci. 2017;13:339–48. [Europe PMC free article] [Abstract] [Google Scholar]

68. Markopoulos GS, Roupakia E, Tokamani M, Chavdoula E, Hatziapostolou M, Polytarchou C. et al. A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol (Dordr) 2017;40:303–39. [Abstract] [Google Scholar]

69. Xia H, Hui KM. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 2012;19:723–30. [Abstract] [Google Scholar]

70. Truong D, Puleo J, Llave A, Mouneimne G, Kamm RD, Nikkhah M. Breast Cancer Cell Invasion into a Three Dimensional Tumor-Stroma Microenvironment. Sci Rep. 2016;6:34094. [Europe PMC free article] [Abstract] [Google Scholar]

71. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER. et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649–56. [Abstract] [Google Scholar]

72. Chabottaux V, Ricaud S, Host L, Blacher S, Paye A, Thiry M. et al. Membrane-type 4 matrix metalloproteinase (MT4-MMP) induces lung metastasis by alteration of primary breast tumour vascular architecture. J Cell Mol Med. 2009;13:4002–13. [Europe PMC free article] [Abstract] [Google Scholar]

73. Khuon S, Liang L, Dettman RW, Sporn PH, Wysolmerski RB, Chew TL. Myosin light chain kinase mediates transcellular intravasation of breast cancer cells through the underlying endothelial cells: a three-dimensional FRET study. J Cell Sci. 2010;123:431–40. [Europe PMC free article] [Abstract] [Google Scholar]

74. Reymond N, d'Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. 2013;13:858–70. [Abstract] [Google Scholar]

75. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ. et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005;65:5278–83. [Abstract] [Google Scholar]

76. Zervantonakis IK, Hughes-Alford SK, Charest JL, Condeelis JS, Gertler FB, Kamm RD. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc Natl Acad Sci U S A. 2012;109:13515–20. [Europe PMC free article] [Abstract] [Google Scholar]

77. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009;69:7135–9. [Europe PMC free article] [Abstract] [Google Scholar]

78. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11:1287–96. [Europe PMC free article] [Abstract] [Google Scholar]

79. Deryugina EI, Zajac E, Zilberberg L, Muramatsu T, Joshi G, Dabovic B, LTBP3 promotes early metastatic events during cancer cell dissemination. Oncogene; 2018. [Europe PMC free article] [Abstract] [Google Scholar]

80. Breznik B, Motaln H, Vittori M, Rotter A, Lah Turnsek T. Mesenchymal stem cells differentially affect the invasion of distinct glioblastoma cell lines. Oncotarget. 2017;8:25482–99. [Europe PMC free article] [Abstract] [Google Scholar]

81. Sugioka K, Mishima H, Kodama A, Itahashi M, Fukuda M, Shimomura Y. Regulatory Mechanism of Collagen Degradation by Keratocytes and Corneal Inflammation: The Role of Urokinase-Type Plasminogen Activator. Cornea. 2016;35(Suppl 1):S59–S64. [Abstract] [Google Scholar]

82. Tian B, Chen X, Zhang H, Li X, Wang J, Han W, Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma. Oncotarget; 2017. [Europe PMC free article] [Abstract] [Google Scholar]

83. Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene. 2014;33:255–68. [Europe PMC free article] [Abstract] [Google Scholar]

84. Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A. et al. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res. 2014;29:1886–99. [Abstract] [Google Scholar]

85. Sigloch FC, Burk UC, Biniossek ML, Brabletz T, Schilling O. miR-200c dampens cancer cell migration via regulation of protein kinase A subunits. Oncotarget. 2015;6:23874–89. [Europe PMC free article] [Abstract] [Google Scholar]

86. Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG, Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene; 2018. [Europe PMC free article] [Abstract] [Google Scholar]

87. Mertens C, Mora J, Oren B, Grein S, Winslow S, Scholich K. et al. Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment. Oncoimmunology. 2018;7:e1408751. [Europe PMC free article] [Abstract] [Google Scholar]

88. Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM. et al. MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions. Cancer Cell. 2017;31:368–82. [Abstract] [Google Scholar]

89. Qi C, Li B, Guo S, Wei B, Shao C, Li J. et al. P-Selectin-Mediated Adhesion between Platelets and Tumor Cells Promotes Intestinal Tumorigenesis in Apc(Min/+) Mice. Int J Biol Sci. 2015;11:679–87. [Europe PMC free article] [Abstract] [Google Scholar]

90. Sidibe A, Ropraz P, Jemelin S, Emre Y, Poittevin M, Pocard M. et al. Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours. Nat Commun. 2018;9:355. [Europe PMC free article] [Abstract] [Google Scholar]

91. Felix K, Gaida MM. Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression. Int J Biol Sci. 2016;12:302–13. [Europe PMC free article] [Abstract] [Google Scholar]

92. Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS. et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res. 2009;15:2433–41. [Europe PMC free article] [Abstract] [Google Scholar]

93. Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, Pignatelli J, Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med; 2017. p. 9. [Abstract] [Google Scholar]

94. Lv Y, Xu C, Zhao X, Lin C, Yang X, Xin X, Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells. ACS Nano; 2018. [Abstract] [Google Scholar]

95. Suchorska WM, Lach MS. The role of exosomes in tumor progression and metastasis (Review) Oncol Rep. 2016;35:1237–44. [Abstract] [Google Scholar]

96. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013;91:431–7. [Europe PMC free article] [Abstract] [Google Scholar]

97. Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K. et al. Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. Cancer Res. 2016;76:5832–44. [Abstract] [Google Scholar]

98. Zhang Z, Li X, Sun W, Yue S, Yang J, Li J. et al. Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis. Cancer Lett. 2017;397:33–42. [Abstract] [Google Scholar]

99. Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G. et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36:53. [Europe PMC free article] [Abstract] [Google Scholar]

100. Shan T, Chen S, Chen X, Lin WR, Li W, Ma J. et al. Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism. Oncol Rep. 2017;37:1971–9. [Europe PMC free article] [Abstract] [Google Scholar]

101. Rabold K, Netea MG, Adema GJ, Netea-Maier RT. Cellular metabolism of tumor-associated macrophages - functional impact and consequences. FEBS Lett; 2017. [Abstract] [Google Scholar]

102. Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47–53. [Europe PMC free article] [Abstract] [Google Scholar]

103. Dehne N, Mora J, Namgaladze D, Weigert A, Brune B. Cancer cell and macrophage cross-talk in the tumor microenvironment. Curr Opin Pharmacol. 2017;35:12–9. [Abstract] [Google Scholar]

104. Zhu H, Guo S, Zhang Y, Yin J, Yin W, Tao S. et al. Proton-sensing GPCR-YAP Signalling Promotes Cancer-associated Fibroblast Activation of Mesenchymal Stem Cells. Int J Biol Sci. 2016;12:389–96. [Europe PMC free article] [Abstract] [Google Scholar]

105. Giuliani M, Janji B, Berchem G. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget. 2017;8:24031–44. [Europe PMC free article] [Abstract] [Google Scholar]

106. Nicodemus CF. Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy. 2015;7:923–39. [Europe PMC free article] [Abstract] [Google Scholar]

107. Liao Z, Tan ZW, Zhu P, Tan NS. Cancer-associated fibroblasts in tumor microenvironment - Accomplices in tumor malignancy. Cell Immunol; 2018. [Abstract] [Google Scholar]

108. Poh AR, Ernst M. Targeting Macrophages in Cancer: From Bench to Bedside. Front Oncol. 2018;8:49. [Europe PMC free article] [Abstract] [Google Scholar]

109. Knutsdottir H, Condeelis JS, Palsson E. 3-D individual cell based computational modeling of tumor cell-macrophage paracrine signaling mediated by EGF and CSF-1 gradients. Integr Biol (Camb) 2016;8:104–19. [Europe PMC free article] [Abstract] [Google Scholar]

110. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. [Abstract] [Google Scholar]

111. Campbell DJ, Koch MA. Treg cells: patrolling a dangerous neighborhood. Nat Med. 2011;17:929–30. [Abstract] [Google Scholar]

112. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423–34. [Abstract] [Google Scholar]

113. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103. [Europe PMC free article] [Abstract] [Google Scholar]

114. Lee GR. Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. Mediators Inflamm. 2017;2017:5458178. [Europe PMC free article] [Abstract] [Google Scholar]

115. Qi W, Huang X, Wang J. Correlation between Th17 cells and tumor microenvironment. Cell Immunol. 2013;285:18–22. [Abstract] [Google Scholar]

116. Shen M, Wang J, Ren X. New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. Front Immunol. 2018;9:470. [Europe PMC free article] [Abstract] [Google Scholar]

117. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K. et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011;71:3505–15. [Europe PMC free article] [Abstract] [Google Scholar]

118. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S. et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A. 2011;108:10662–7. [Europe PMC free article] [Abstract] [Google Scholar]

119. Horikawa M, Minard-Colin V, Matsushita T, Tedder TF. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest. 2011;121:4268–80. [Europe PMC free article] [Abstract] [Google Scholar]

120. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17:1371–80. [Abstract] [Google Scholar]

121. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071–121. [Europe PMC free article] [Abstract] [Google Scholar]

122. Swartz MA, Lund AW. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer. 2012;12:210–9. [Abstract] [Google Scholar]

123. Harrell CR, Simovic Markovic B, Fellabaum C, Arsenijevic A, Djonov V, Volarevic V. Molecular mechanisms underlying therapeutic potential of pericytes. J Biomed Sci. 2018;25:21. [Europe PMC free article] [Abstract] [Google Scholar]

124. Qu Y, Zhao G, Li H. Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment. Front Immunol. 2017;8:1675. [Europe PMC free article] [Abstract] [Google Scholar]

125. Gasche JA, Hoffmann J, Boland CR, Goel A. Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer. 2011;129:1053–63. [Europe PMC free article] [Abstract] [Google Scholar]

126. Santibanez JF, Quintanilla M, Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2011;121:233–51. [Abstract] [Google Scholar]

127. Ai S, Cheng XW, Inoue A, Nakamura K, Okumura K, Iguchi A. et al. Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. Biochem Biophys Res Commun. 2007;364:395–401. [Abstract] [Google Scholar]

128. Aljada A, O'Connor L, Fu YY, Mousa SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis. 2008;11:361–7. [Abstract] [Google Scholar]

129. Zhao D, Tu Y, Wan L, Bu L, Huang T, Sun X. et al. In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging. PLoS One. 2013;8:e71472. [Europe PMC free article] [Abstract] [Google Scholar]

130. Lei H, Deng CX. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. Int J Biol Sci. 2017;13:1163–71. [Europe PMC free article] [Abstract] [Google Scholar]

131. Ostman A. PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment. Adv Drug Deliv Rev. 2017;121:117–23. [Abstract] [Google Scholar]

132. Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med; 2017. [Abstract] [Google Scholar]

133. Nasser MW, Elbaz M, Ahirwar DK, Ganju RK. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins. Cancer Lett. 2015;365:11–22. [Abstract] [Google Scholar]

134. Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr Pharm Des. 2010;16:1284–90. [Abstract] [Google Scholar]

135. Longmate W, DiPersio CM. Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment. F1000Res. 2017;6:1612. [Europe PMC free article] [Abstract] [Google Scholar]

Articles from International Journal of Biological Sciences are provided here courtesy of Ivyspring International Publisher

Full text links

Read article at publisher's site: https://doi.org/10.7150/ijbs.25720

Read article for free, from open access legal sources, via Unpaywall: http://www.ijbs.com/v14p2083.pdf

Citations & impact

Impact metrics

140

Citations

Jump to Citations

Citations of article over time

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.7150/ijbs.25720

Supporting

Mentioning

Contrasting

165

Article citations

Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities.
Jiang W, Jin WL, Xu AM
Int J Biol Sci, 20(6):2044-2071, 17 Mar 2024
Cited by: 0 articles | PMID: 38617549 | PMCID: PMC11008265
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes in Resectable Gastric Cancer: Analysis from a Western Academic Center.
Yee EJ, Gilbert D, Kaplan J, Wani S, Kim SS, McCarter MD, Stewart CL
Cancers (Basel), 16(7):1428, 07 Apr 2024
Cited by: 0 articles | PMID: 38611107 | PMCID: PMC11010931
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Human Chorionic Gonadotropin Regulates the Smad Signaling Pathway by Antagonizing TGF-β in Giant Cell Tumor of Bone.
Xu T, Xu S, Ma G, Chang J, Zhang C, Zhou P, Wang C, Xu P, Yang J, Hu Y, Wu Y
Recent Pat Anticancer Drug Discov, 19(2):188-198, 01 Jan 2024
Cited by: 0 articles | PMID: 38214358 | PMCID: PMC10804236
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The role of CSTF2 in cancer: from technology to clinical application.
Ding J, Su Y, Liu Y, Xu Y, Yang D, Wang X, Hao S, Zhou H, Li H
Cell Cycle, 22(23-24):2622-2636, 01 Dec 2023
Cited by: 0 articles | PMID: 38166492
Review
The role of host response to chemotherapy: resistance, metastasis and clinical implications.
Deo A, Sleeman JP, Shaked Y
Clin Exp Metastasis, 24 Nov 2023
Cited by: 0 articles | PMID: 37999904
Review

Go to all (140) article citations

Search life-sciences literature (44,013,254 articles, preprints and more)

Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation.

Affiliations

Authors

ORCIDs linked to this article

Abstract

Free full text

Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation

Abstract

Introduction

Functions of the Major Components in Tumor Microenvironment

Stromal Cells in TME

Table 1

ECM in TME

Secreted Factors in TME

Table 2

The Effects of Stromal Cells on Metastasis Initiation

The Effects of Stromal Cells on Angiogenesis

The Effects of Stromal Cells on EMT

The Effects of Stromal Cells on Invasion and Intravasation

Conclusion and Future Aspects

Acknowledgments

References

Full text links

Citations & impact

Impact metrics

Citations of article over time

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.7150/ijbs.25720

Article citations

Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities.

Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes in Resectable Gastric Cancer: Analysis from a Western Academic Center.

Human Chorionic Gonadotropin Regulates the Smad Signaling Pathway by Antagonizing TGF-β in Giant Cell Tumor of Bone.

The role of CSTF2 in cancer: from technology to clinical application.

The role of host response to chemotherapy: resistance, metastasis and clinical implications.

Similar Articles

The landscape of long non-coding RNAs in tumor stroma.

Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.

The Microenvironment of Lung Cancer and Therapeutic Implications.

Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex.

Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.

Similar Articles

The landscape of long non-coding RNAs in tumor stroma.
Life Sci, 264:118725, 06 Nov 2020

Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.
Dev Dyn, 247(3):405-431, 18 Sep 2017

The Microenvironment of Lung Cancer and Therapeutic Implications.
Adv Exp Med Biol, 890:75-110, 01 Jan 2016

Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex.

Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Adv Exp Med Biol, 1277:143-158, 01 Jan 2020